anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Osteoarthritis (OA), characterized by chronic pain, significantly affects the quality of life of affected individuals. Key factors in OA pathogenesis include cartilage degradation and inflammation. Signal transducer and activator of transcription 3 (STAT3), a member of the STAT protein family, plays a pivotal role in mediating inflammation. STX-0119 has been verified as a small molecular compound that can specifically inhibit STAT3. However, the efficacy of STX-0119 in the treatment of OA remains to be evaluated. Therefore, the aim of this study was to explore the therapeutic effects and molecular mechanisms of STX-0119 in the treatment of OA. We found that the expression of phosphorylated STAT3 is upregulated in human OA cartilage as well as in the cartilage of a mouse model of OA. In vivo, joint injection of STX-0119 into OA mice alleviated cartilage degeneration without affecting the subchondral bone. Additionally, STX-0119 could inhibit the phosphorylation of STAT3 in the cartilage. In vitro, STX-0119 suppressed inflammatory responses in chondrocytes and promoted anabolic metabolism in an interleukin-1β-induced chondrocyte inflammation model. Additionally, the results of transcriptome sequencing and lentiviral infection assays demonstrated that in chondrocytes, STX-0119 induces the upregulation of peroxisome proliferators-activated receptor gamma (PPARγ) expression by inhibiting STAT3 phosphorylation. Finally, in ex vivo cultures of human cartilage samples, STX-0119 was reaffirmed to inhibit cartilage degeneration via the STAT3/PPARγ signaling pathway. Together, our findings support the potential of STX-0119 for development as a therapeutic agent targeting STAT3 for the treatment of OA.
Placebo injections consisting of sterile water (0.1 mL) in place of Vacc-4x. Placebo injections consisting of sterile water (0.1 mL) in place of Leukine.
Although the incidence of cervical cancer (CC) has been reduced in high-income countries due to human papillomavirus (HPV) vaccination and screening strategies, it remains a significant public health issue that poses a threat to women's health in low-income countries. Here, we perform a comprehensive proteogenomic profiling of CC tumors obtained from 139 Chinese women. Integrated proteogenomic analysis links genetic aberrations to downstream pathogenesis-related pathways and reveals the landscape of HPV-associated multi-omic changes. EP300 is found to enhance the acetylation of FOSL2-K222, consequently accelerating the malignant proliferation of CC cells. Proteomic stratification identifies three patient subgroups with distinct features in prognosis, genetic alterations, immune infiltration, and post-translational modification regulations. PRKCB is further identified as a potential radioresponse-related biomarker of CC patients. This study provides a valuable public resource for researchers and clinicians to delve into the molecular basis of CC, to identify potential treatments and to ultimately advance clinical practice.
In the current legislativ context notably the Clayes Leonetti law, a very large majority of ICU (Intensive Care Unit) patients die with the establishement of a procedure for the limitation and cessation of therapeutics (LAT). During a viral pandemic, medical resources can be saturated, limiting reflexive abilities in favour of binary decisions. This sorting of patients leads to LAT that could be performed without the elementary modalities stated by the law. Thus, arbitrary medical decisions made alone could expose patients to unjustified " loss of luck ". Increasing the resources mobilized during a pandemic must not make us forget the quality of care provided for the benefit of quantity. In therefore seems legitimate to keep the LAT modalities to ensure our ethical principles. No work in the literature based on actual facts explores the impact of a pandemic on compliance with and maintenance of ethical principles and the legisltaive framework, in particular as regards the procedures of the application of LAT.

The purpose of this study is to assess whether the terms of the LAT are being complied during a pandemic for patients with or without Covid.
PURPOSE:To obtain a cosmetic, stably containing kojic acid without any coloring with time, especially coloring by heat with time by blending kojic acids together with superoxide dismutase and/or sodium hydrogensulfite. CONSTITUTION:A safe cosmetic containing kojic acid expressed by the formula (R<1> and R<2> are H, 3-22C acyl or 3-22C alkyl) or its derivative [e.g. kojic acid monobutyrate or kojic acid dibtyrate (in an amount of preferably about 0.0001-5.0wt.% based on the whole composition)] and superoxide dismutase (which is a superoxide eliminating enzyme used in an amount of preferably about 0.00001-1 pt.wt. based on 1 pt.wt. kojic acids) and/or sodium hydrogensulfite (used in an amount of preferably about 0.0001-1 pt.wt. based on 1 pt.wt. kojic acids). The aforementioned cosmetic has high beautifying and whitening effects and can be used as milky lotions, creams, packs, toilet water, foundations, etc.
Obstructive sleep apnea (OSA) is characterized by repetitive episodes of upper airway obstruction during sleep that provoke frequents arousals, sleep fragmentation, oxygen desaturation, and excessive daytime sleepiness. OSA may contribute to the development of systemic hypertension, cardiovascular disease. Many studies has reported a crucial role for the prostaglandin D system in sleep regulation. In addition, it has been described urinary or blood levels of prostaglandins was higher in the patients with hypertension, diabetes mellitus, and these values were associated with the severity of coronary artery disease. However, the relation between alterations of prostaglandin D system and sleep architecture, sleepiness, and clinical outcomes such as hypertension, arteriosclerosis in the patients with OSA are not known. Additionally, after CPAP treatment, we will investigate the association between change of prostaglandin system and sleep architecture, sleepiness, clinical outcomes.
The present invention discloses an extraction of herpetospermumpeduncul-osum (Sex.) baill. And herpetin of cucurbitaceous plant, and also relates to a preparation method for the extraction of herpetospermumpeduncul-osum (Sex.) baill. And the herpetin, a medicine composition of the extraction of herpetospermumpeduncul-osum (Sex.) baill., the herpetin and a derivative of the herpetin, and a purpose of the herpetin, the derivative of the herpetin and the medicine composition as medicine, particularly a purpose for preparing antivirus medicine, hepatic injury resistant medicine and antineoplastic medicine. The present invention is verified by a cell experiment and an animal experiment, and herpetospermumpeduncul-osum (Sex.) baill. Has the advantages of high reactivity and little toxicity.
BACKGROUND: Vascular graft infection is a very complex disease. Although complete excision of the infected grafts with extra-anatomic bypass or in situ reconstruction is a general treatment strategy, some concerns including reinfection in the new graft remain.
CASE REPORT: An 88 year-old man presented to the hospital with abdominal swelling and bleeding. The patient had undergone revascularization for aorto-iliac occlusive disease twice in the past. The first procedure had been performed 15 years previously, with right ilio-femoral bypass grafting for right iliac artery occlusion and stent implantation for left iliac artery stenosis. The second procedure had been performed 10 years previously, with aorta-to-left femoral and left-to-right femoro-femoral bypass grafting because the terminal aorta, the first ilio-femoral bypass graft, and the stent of the left iliac artery had been occluded. The patient was diagnosed with vascular graft infection, and endovascular therapy was selected as the revascularization method prior to graft excision. It was successfully performed using various devices and techniques, followed by graft excision without critical limb ischemia.
CONCLUSION: This case demonstrates that endovascular therapy prior to graft excision can be an alternative revascularization method for vascular graft infection after bypass surgery for aorto-iliac occlusive disease.
Conventional therapy includes range of motion exercises, walking and balance exercises. The treatment period will be 5 days a week, a total of 20 sessions for 4 weeks. The exercises will last for half an hour daily.
As the life expectancy of the population continues to increase, more facial-rejuvenating procedures are sought. As the number of facelift procedures increases, it is mandatory to acknowledge, and most importantly prevent, any possible associated complications. One of the complications after rhytidectomy, and a sign of facelift, is the so-called "pixie ear deformity" or "bat ear." This is regarded as a telltale sign of a facelift procedure and appears to be identified in 5% of earlobe inset cases. The ear's location is a crucial hallmark of an aesthetically pleasing face, not only by itself but also in relation with other aesthetic units. When performing a facelift procedure, tension vectors of the rhytidectomy flap could cause alterations in ear's position and appearance: the ear loses its great mobility and becomes more fixed in its acquired position, resulting in a "stuck-on" appearance. The auricle is displaced following an anteroinferior direction, with the otobasion inferius (the most caudal anterior attachment of the earlobe to the cheek) being dislocated from its original more posterior and upper position to a new more anterior and caudal location. The displacement of the auricle is usually accompanied by distortion of the earlobe rotating forward and becoming more anterior than the rest of the ear. In recent decades, many techniques and procedures have been described to prevent and correct the pixie ear; in this review, we aim to analyze and describe them comprehensively.
INTRODUCTION: Neuropeptide Y is a neurotransmitter in the nervous system and belongs to the orexigenic system that increases appetite. Its excessive secretion leads to obesity. Leptin is a pro-inflammatory adipokine (produced in adipose tissue) induced in obesity and may mediate increased antitumor immunity in obesity (including the promotion of M1 macrophages). Leptin and neuropeptide Y gene polymorphisms, causing increased leptin levels and the occurrence of obesity, and lipid profile disorders, may increase the effectiveness of immunotherapy.
MATERIALS AND METHODS: In 121 patients with advanced NSCLC without mutations in the EGFR gene and rearrangements of the ALK and ROS1 genes, undergoing immunotherapy (1st and 2nd line of treatment) or chemoimmunotherapy (1st line of treatment), we assessed BMI, lipid profile, PD-L1 expression on cancer cells using the immunohistochemical method (clone SP263 antibody), leptin concentration in blood serum by ELISA, polymorphisms in the promoter region of the genes for leptin (LEP) and neuropeptide Y (NPY) by real-time PCR.
RESULTS: Leptin concentration was significantly higher in obese patients than in patients with normal or low weight (p = 0.00003) and in patients with disease stabilization compared to patients with progression observed during immunotherapy (p = 0.012). Disease control occurred significantly more often in patients with the GA or AA genotype than patients with the GG genotype in the rs779039 polymorphism of the LEP gene. The median PFS in the entire study group was five months (95% CI: 3-5.5), and the median OS was 12 months (95% CI: 8-16). Median PFS was highest in patients with TPS ≥ 50% (6.5 months) and in obese patients (6.6 months). Obese patients also had a slightly longer median OS compared to other patients (23.8 vs. 13 months). The multivariate Cox logistic regression test showed that the only factor reducing the risk of progression was TPS ≥ 50% (HR = 0.6068, 95% CI: 0.4001-0.9204, p = 0, 0187), and the only factor reducing the risk of death was high leptin concentration (HR = 0.6743, 95% CI: 0.4243-1.0715, p = 0.0953).
CONCLUSION: Assessment of nutritional status, serum leptin concentration and polymorphisms in the LEP gene may be of additional importance in predicting the effectiveness of immunotherapy and chemoimmunotherapy in patients with advanced NSCLC.
A pipelle sample will be taken on day 21 of the cycle before administration of GNRHa. Exact timing will be performed by counting 7 days from the LH surge.
The waitlist control group will not receive any additional support or interventions whilst waiting to receive the ReST intervention. These participants will be asked to report any psychological interventions or psychotropic medications that they have accessed outside of the trial whilst they are on the waiting list. Wait list control participants will be offered the ReST intervention following their 6-week follow-up assessment.
The present invention provides a medicine for treating hyperosteogeny, which is composed of main medicines and auxiliary medicines, wherein desertliving cistanche, degelatined deer-horn, pyrola herb, long-noded pit viper, pangolin scale, kudzuvine root, etc. are used as the main medicines; matrimony vine, laminaria, safflower, common monkshood mother root, malt, corydalis tuber, etc. are used as auxiliary medicines. The medicine has the functions of nourishing the kidney, softening hard masses, strengthening the spleen and stomach, eliminating dampness, killing pains, rapidly infiltrating, etc. The medicine has the advantages of short course of treatment, enhancement of calcium ion metabolism, effective prevention of osteophyma formation, no toxic side effect, convenient and taking and portability. In addition, the effective rate of the medicine can reach 98% and the curative rate of the medicine can reach more than 90%. Thereby, the medicine is an effective medicine for treating hyperosteogeny at present.
Participants receive up to 12 doses of telcagepant (280 mg tablet/capsule 300 mg), orally, and placebo to acetaminophen/paracetamol (APAP) (2- 500 mg dry filled capsules), orally, for up to 12 migraine attacks in Period 1 (6 weeks). Participants receive APAP and placebo to telcagepant for up to 12 doses, for up to 12 migraine attacks in Period 2 (6 weeks). The participant may take a blinded optional second dose of study medication or their own rescue medication if 2 hours after initial treatment, the participant still has a moderate or severe migraine headache or if the headache has returned.
PURPOSE: A cosmetic material algal proteins or derivatives thereof obtained from naturally occurring algae containing the genus Porphyra, the genus Undaria, Chlorella or Spirulina as a main material is provided. It has high skin compatibility and suitable astringent properties, supplies gloss and moisture to skin while providing the hair with softness, moisturization and gloss and can be used in skin cosmetics, hair cosmetics, bath agents etc. CONSTITUTION: The cosmetic material contains algal proteins or derivatives thereof. The algae are naturally occurring algae and obtained from preferably algae of the genus Porphyra, the genus Undaria, Chlorella or Spirulina. In the method for preparing algal proteins, algae are crushed or ground to break the cell walls of algae and then extracted with a solvent. The algal protein derivatives are obtained by esterification, silylation, cationization or acylation of algal proteins. The cosmetic material also contains peptides or derivatives thereof obtained by treatment of the algae themselves or by enzymatic decomposition, acid or alkali hydrolysis of the proteins or heating extraction under pressure.
Obsessive-compulsive disorder (OCD) typically starts between childhood and early adulthood and is characterized by the presence of obsessions and/or compulsions and a typically chronic clinical course. Around one-third of OCD patients fail to benefit significantly from first-line treatment, e.g., serotonin reuptake inhibitors (SRIs) or cognitive behavioral therapy (CBT). Combining, augmenting, and switching strategies as second-line treatments also fail to bring much benefit to these patients. When the first-line and second-line treatments fail, alternative treatments (e.g., non-invasive brain stimulation techniques) should be considered. A proposed pathophysiology of OCD is the dysfunction of cortico-striato-thalamo-cortical circuitry including the medial prefrontal cortex \[i.e., supplementary motor area (SMA) and anterior cingulate cortex (ACC)\], the dorso-lateral prefrontal cortex (DLPFC), the orbitofrontal cortex (OFC), and the basal ganglia. Among novel therapeutic options of non-invasive brain stimulation, transcranial direct current stimulation (tDCS) has shown positive results (e.g., cathodal tDCS over the pre-SMA, tDCS with the cathode over the left OFC and the anode over the right cerebellum, and tDCS with anode over Pre-SMA and cathode over right supra-orbital area) in treatment-resistant OCD. However, there is unclear evidence regarding the best tDCS montage for treatment-resistant OCD. This study investigates the effects of three different tDCS montages in reducing the symptoms of patients with treatment-resistant OCD. Eligible participants with treatment-resistant OCD will be allocated randomly into three groups of different tDCS montages \[1. The right cerebellum (anode) and the left OFC (cathode) tDCS; 2. The bilateral pre-SMA (cathode) and right deltoid (reference) tDCS; 3. The left OFC (cathode 1), bilateral pre-SMA (cathode 2), and right deltoid (reference) tDCS\]. Patients will receive twice-daily sessions separated by at least 1 h for 10 consecutive weekdays. One session of tDCS consists in delivering a direct current of 2 mA during 20 min. The primary outcome is the difference in the change of the score of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS) between three different montages of tDCS. Electrical activity of the brain as measured by EEG, autonomic function as measured by heart rate variability, and cognitive functioning as secondary outcomes will be measured before and after three different montages of tDCS.
First, the clinicians will be trained on how to use the PCI-TC in their outpatient clinics. A new group of patients will then be identified and recruited for the phase two study. Patients from this new group will be given the PCI-TC in a quiet area just off the waiting area prior to the consultation. They will be asked to tick items on the PCI-TC list which they wish to discuss. The clinicians will conduct the consultation using the ticked PCI-TC as a guide and discuss with patients regarding the treatment plan for their thyroid cancer. The patients will be approached for interview within 14 days after their consultations. The clinicians will be approached for interview after all recruited patients in phase two study have had their consultation regarding their cancer treatment.
Devantier-Thomas, B, Deakin, GB, Crowther, F, Schumann, M, and Doma, K. The impact of exercise-induced muscle damage on various cycling performance metrics: a systematic review and meta-analysis. J Strength Cond Res 38(8): 1509-1525, 2024-This systematic review and meta-analysis examined the impact of exercise-induced muscle damage (EIMD) on cycling performance. The primary outcome measure was cycling performance, whereas secondary outcome measures included creatine kinase (CK), delayed-onset muscle soreness (DOMS), and muscular contractions. Data were extracted and quantified through forest plots to report on the standardized mean difference and p values. The meta-analysis showed no significant change in oxygen consumption at 24-48 hours ( p > 0.05) after the muscle damage protocol, although ventilation and rating of perceived exertion significantly increased ( p < 0.05) during submaximal cycling protocols. Peak power output during both sprint and incremental cycling performance was significantly reduced ( p < 0.05), but time-trial and distance-trial performance showed no change ( p > 0.05). Measures of CK and DOMS were significantly increased ( p < 0.05), whereas muscular force was significantly reduced following the muscle-damaging protocols ( p < 0.05), confirming that cycling performance was assessed during periods of EIMD. This systematic review showed that EIMD affected both maximal and submaximal cycling performance. Therefore, coaches should consider the effect of EIMD on cycling performance when implementing unaccustomed exercise into a cycling program. Careful consideration should be taken to ensure that additional training does not impair performance and endurance adaptation.
BACKGROUND: Severe trauma is associated with systemic inflammation and organ dysfunction. Preclinical rodent trauma models are the mainstay of postinjury research but have been criticized for not fully replicating severe human trauma. The aim of this study was to create a rat model of multicompartmental injury which recreates profound traumatic injury.
METHODS: Male Sprague-Dawley rats were subjected to unilateral lung contusion and hemorrhagic shock (LCHS), multicompartmental polytrauma (PT) (unilateral lung contusion, hemorrhagic shock, cecectomy, bifemoral pseudofracture), or naïve controls. Weight, plasma toll-like receptor 4 (TLR4), hemoglobin, spleen to body weight ratio, bone marrow (BM) erythroid progenitor (CFU-GEMM, BFU-E, and CFU-E) growth, plasma granulocyte colony-stimulating factor (G-CSF) and right lung histologic injury were assessed on day 7, with significance defined as p values <0.05 (*).
RESULTS: Polytrauma resulted in markedly more profound inhibition of weight gain compared to LCHS (p = 0.0002) along with elevated plasma TLR4 (p < 0.0001), lower hemoglobin (p < 0.0001), and enlarged spleen to body weight ratios (p = 0.004). Both LCHS and PT demonstrated suppression of CFU-E and BFU-E growth compared to naïve (p < 0.03, p < 0.01). Plasma G-CSF was elevated in PT compared to both naïve and LCHS (p < 0.0001, p = 0.02). LCHS and PT demonstrated significant histologic right lung injury with poor alveolar wall integrity and interstitial edema.
CONCLUSIONS: Multicompartmental injury as described here establishes a reproducible model of multicompartmental injury with worsened anemia, splenic tissue enlargement, weight loss, and increased inflammatory activity compared to a less severe model. This may serve as a more effective model to recreate profound traumatic injury to replicate the human inflammatory response postinjury.
<P>PROBLEM TO BE SOLVED: To provide an aging inhibitor or a cell activator having high aging inhibitory effect and cell activating effect and causing no deterioration in a skin care preparation for external use containing the same, and to provide the skin care preparation for external use containing the same, stable with time and having aging inhibitory effect.  <P>SOLUTION: The aging inhibitor or the cell activator comprises as the active ingredient a liquid obtained by separation from a squeezed liquid derived from Lonicera caerulea L. var. emphyllocalyx or Lonicera caerulea L. var. edulis through concentrating or distilling the squeezed liquid. The skin care preparation for external use contains the aging inhibitor or the cell activator. Another version of the above skin care preparation contains, in addition to the aging inhibitor or the cell activator, one or more medicinal agents selected from another cell activator, antioxidant, moisturizer and ultraviolet inhibitor.  <P>COPYRIGHT: (C)2004,JPO